Executive Summary
The six SPAC filings reveal a bifurcated US M&A landscape with fresh momentum in de-SPAC transactions and IPOs contrasted by compliance distress and financing strains; Crown Reserve's Carvix merger and Future Money's $115.6M IPO (including $112M public + $3.04M private placement) signal robust deal activity, while JENA's NYSE non-compliance and DMII's sponsor transition highlight sector headwinds. No explicit YoY/QoQ financial trends or operational metrics reported across filings, but forward-looking timelines cluster catalysts in 45 days (JENA plan), 4-6 months (DMII deal execution), and 3-year earnouts (Crown). Insider activity absent; capital allocation focused on trust deposits (Future Money) and debt amendments (Inflection Point note up 14% QoQ from $700k to $800k). High materiality developments (avg 7.5/10) underscore SPAC revival potential amid regulatory risks, with positive sentiment in 2/6 filings driving takeover opportunities. Portfolio-level pattern: 4/6 newly published filings show financing/de-SPAC urgency, implying accelerated M&A timelines versus stagnant peers.
Tracking the trend? Catch up on the prior US Merger & Acquisition SEC Filings digest from April 01, 2026.
Investment Signals(11)
- Crown Reserve Acquisition Corp. Iβ(BULLISH)β²
Business Combination Agreement with Carvix includes PIPE financing, ELOC commitment, and 3-year earnout shares tied to post-merger EBITDA/revenue; unanimous board approval
- Future Money Acquisition Corpβ(BULLISH)β²
Completed IPO raising $112M public + $3.04M private placement (total $115.6M trust after loan offset), units trading on Nasdaq (FMACU/FMAC/FMCR)
- β²
Secured $1.4M financing commitment ($150k received, $300k due Mar 30, $950k escrow) for de-SPAC prep despite sponsor issues; 35% discount convertibles
- β²
Amended promissory note +14% QoQ to $800k principal (from $700k Jan 2026, original $500k 2025) for working capital, no other terms changed
- Crown Reserve Acquisition Corp. Iβ(BULLISH)β²
Stockholder support agreements from key Carvix holders and Investor Rights Agreement enhance deal certainty
- Future Money Acquisition Corpβ(BULLISH)β²
Audited balance sheet (Exhibit 99.1) confirms $112.56M trust integrity post-IPO, positioning for rapid target pursuit
- JENA ACQUISITION Corp IIβ(NEUTRAL)β²
Plans de-SPAC within 18 months to regain NYSE compliance (300 public shareholders), focusing real estate/construction targets
- NMP Acquisition Corp.β(NEUTRAL)β²
Released 2025 PFIC statement showing minimal earnings ($0.0006411382/unit/day) and zero gains/distributions, enabling QEF elections
- β²
6-month exclusivity and investor ROFR on extra capital beyond $1.4M signal committed path to transaction
- Crown Reserve Acquisition Corp. Iβ(BULLISH)β²
Domestication to Delaware + merger structure positions Carvix as wholly-owned sub, with min PIPE threshold
- β²
Note governed by NY law, assigned from original sponsor, reflects ongoing operational funding vs peers without amendments
Risk Flags(8)
- JENA ACQUISITION Corp II/Regulatoryβ[HIGH RISK]βΌ
NYSE non-compliance notice (Section 802.01A, <300 public shareholders); 45-day plan review, 18-month cure via de-SPAC or delisting
- βΌ
Non-performing sponsor under legal constraints requires transition; only $150k/$1.4M received to date
- Inflection Point Acquisition Corp. V/Debtβ[MEDIUM RISK]βΌ
Promissory note principal up 14% QoQ to $800k (from $700k), following +40% prior amendment, signals cash burn
- JENA ACQUISITION Corp II/Listingβ[HIGH RISK]βΌ
No immediate trading halt but ongoing shareholder deficiency poses de-SPAC delays vs peers like Crown/Future Money
- βΌ
Must execute investor-introduced deal in principle within 4 months (by ~Jul 23, 2026) or risk financing lapse
- Crown Reserve Acquisition Corp. I/Executionβ[MEDIUM RISK]βΌ
Relies on min PIPE investment and shareholder approval; earnouts over 3 years tied to unproven EBITDA/revenue
- NMP Acquisition Corp./Taxβ[LOW RISK]βΌ
PFIC status with zero 2025 gains/distributions may deter US tax-sensitive investors electing QEF
- Inflection Point Acquisition Corp. V/Liquidityβ[MEDIUM RISK]βΌ
Cumulative note advances (original $500k to $800k over 14 months) without revenue indicate pre-de-SPAC strain vs new IPOs
Opportunities(8)
- Crown Reserve Acquisition Corp. I/De-SPACβ(OPPORTUNITY)β
Fresh merger with Carvix (Mar 30 agreement) offers arbitrage play pre-shareholder vote; PIPE/ELOC + earnouts undervalue growth potential
- Future Money Acquisition Corp/IPOsβ(OPPORTUNITY)β
$115.6M trust post-IPO (Mar 30) enables aggressive target bidding; early Nasdaq entry vs distressed SPACs like JENA
- β
$1.4M commitment + 35% discount notes positions for de-SPAC in 4-6 months; ROFR protects upside
- JENA ACQUISITION Corp II/Turnaroundβ(OPPORTUNITY)β
Real estate/construction focus + 18-month de-SPAC plan could resolve NYSE issue; monitor 45-day submission for catalysts
- Crown Reserve Acquisition Corp. I/Earnoutsβ(OPPORTUNITY)β
3-year performance shares on Carvix EBITDA/revenue create aligned incentives; relative to sector, high materiality 10/10
- Future Money Acquisition Corp./Rightsβ(OPPORTUNITY)β
Units with 1/5 share rights upon business combo offer leveraged upside vs plain shares in peers
- β
Recent $100k note increase funds de-SPAC hunt; potential for quick deal vs timeline-constrained DMII
- NMP Acquisition Corp./Tax Clarityβ(OPPORTUNITY)β
PFIC statement facilitates QEF elections, reducing tax drag for holders vs non-filers
Sector Themes(5)
- SPAC Financing Strain(THEME)β
2/6 filings (DMII $1.4M commitment, Inflection +14% QoQ note to $800k) highlight cash needs for audits/Nasdaq/de-SPAC, implying sector-wide liquidity pressure vs robust IPOs
- De-SPAC Momentum vs Distress(THEME)β
1/6 announced deal (Crown positive) amid 1 delisting risk (JENA) and 1 sponsor transition (DMII); 50% of new filings show urgency
- Timeline Clustering(THEME)β
Catalysts in 45 days (JENA plan), 4 months (DMII agreement), 6 months (exclusivity), 18 months (JENA cure); accelerates M&A vs stagnant 2025 PFIC peers
- High Materiality New Issues(THEME)β
4/4 newly published filings avg 8/10 materiality (Crown/Future 10/10), signaling investor focus on active SPACs over routine (NMP 3/10)
- Sentiment Bifurcation(THEME)β
Positive in IPO/de-SPAC (2/6), negative/mixed in distress (2/6), neutral in ops/tax (2/6); opportunities in positives outweigh risks
Watch List(8)
- π
Submission within 45 days (~May 16, 2026) for compliance regain; watch approval/rejection impacting listing
Agreement in principle within 4 months (~Jul 23, 2026); monitor $300k tranche and escrow release
Post-Mar 30 Business Combination; track PIPE close, ELOC activation, and earnout milestones over 3 years
$800k note drawdown post-Apr 2 amendment; watch for further increases signaling delays vs peers
- π
Fresh $115.6M trust post-Mar 30 IPO; monitor initial business combination announcement timeline
6-month period (~Sep 23, 2026); watch ROFR invocation on additional capital
3-year post-merger EBITDA/revenue triggers; first-year check ~2027 for share vesting
- π
Apr 3 release referenced 802.01B variance; track de-SPAC target in real estate/construction
Filing Analyses(6)
03-04-2026
On April 1, 2026, Jena Acquisition Corporation II, a blank check SPAC, received a notice from NYSE Regulation for non-compliance with Section 802.01A of the NYSE Listed Company Manual, failing to maintain a minimum of 300 public shareholders. The company plans to submit a business plan within 45 days outlining regaining compliance within 18 months through a de-SPAC transaction, with no immediate impact on the listing or trading of its securities (JENA.U, JENA, JENA.R). This deficiency highlights ongoing challenges in attracting sufficient public shareholders, posing delisting risks if unresolved.
- Β·Company intends to focus on targets benefiting from management expertise in real estate & construction.
- Β·Press release issued April 3, 2026, references slightly different rule (Section 802.01B).
- Β·NYSE has 45 days to review the submitted business plan.
03-04-2026
Drugs Made in America Acquisition Corp II (DMIIU) entered into a Definitive Investment and Sponsor Transition Agreement on March 23, 2026, with Tal Alpha Yezum Vekidum Asakim (2003) LTD for a total financing commitment of $1,400,000 to fund audit, SEC filings, Nasdaq fees, legal costs, and de-SPAC transaction preparation. Of this, $150,000 has been received, $300,000 is due by March 30, 2026, and $950,000 is reserved in escrow; however, the existing sponsor is described as non-performing and subject to legal constraints, necessitating a transition facilitated by the Company. The agreement includes a 4-month timeline to execute an investor-introduced transaction agreement in principle and 6-month exclusivity, with convertible notes at a 35% discount to post-merger market value.
- Β·Exclusivity period: 6 months
- Β·Timeline: Execute agreement in principle within 4 months
- Β·Investor right of first refusal on additional capital beyond $1.4M
- Β·No claim on trust account for convertible notes
- Β·Maturity of Interim Convertible Note: 9 months from issuance
- Β·Governing law: Cayman Islands
- Β·Prior agreements superseded: LOI dated March 5, 2026; Addendum No. 1 dated March 9, 2026; Interim Convertible Note dated March 9, 2026; Sponsor Standstill Agreement dated March 18, 2026
03-04-2026
Inflection Point Acquisition Corp. V entered into Amendment No. 2 to its Promissory Note with Inflection Point Fund I LP on April 2, 2026, increasing the principal amount from $700,000 to $800,000 to provide additional working capital. This follows an original note dated February 12, 2025, for up to $500,000 (fully advanced) originally from Maywood Sponsor, LLC and assigned to the Payee on September 9, 2025, with a first amendment on January 7, 2026, raising it to $700,000. No other changes to the note terms were made.
- Β·Promissory Note originally executed by Maywood Acquisition Corp. (former name of Inflection Point Acquisition Corp. V)
- Β·Governed by the laws of the State of New York
- Β·SEC 8-K filed on April 03, 2026, covering Items 1.01, 2.03, and 9.01
03-04-2026
Crown Reserve Acquisition Corp. I (SPAC), a Cayman Islands exempted company, entered into a Business Combination Agreement dated March 30, 2026, with CRAC Merger Sub Inc. and Carvix, Inc., providing for SPAC's domestication to Delaware followed by a merger where Merger Sub merges with Carvix, with Carvix surviving as SPAC's wholly-owned subsidiary. The transaction includes stockholder support agreements from key Carvix stockholders, plans for PIPE financing meeting a minimum investment amount and a committed ELOC, an Investor Rights Agreement, and earnout shares for eligible Carvix equityholders based on post-merger EBITDA and revenue performance over three years. All relevant boards have unanimously approved the agreement and recommended it to shareholders.
03-04-2026
Future Money Acquisition Corporation consummated its initial public offering (IPO) on March 30, 2026, selling 11,200,000 units at $10.00 per unit, generating gross proceeds of $112,000,000. Simultaneously, the company completed a private placement of 304,000 units to sponsor Future Wealth Capital Corp. at $10.00 per unit for $3,040,000 in gross proceeds. A total of $112,560,000 from both was placed in a trust account, after offsetting a $290,855 sponsor loan, with an audited balance sheet issued as Exhibit 99.1.
- Β·Units consist of one ordinary share (par value $0.0001) and one right entitling holder to one-fifth of one ordinary share upon initial business combination.
- Β·Trading symbols: FMACU (Units), FMAC (Ordinary Shares), FMACR (Rights) on Nasdaq.
- Β·Audited balance sheet as of March 30, 2026, included as Exhibit 99.1.
03-04-2026
NMP Acquisition Corp., a Cayman Islands-incorporated blank check company, filed an 8-K on April 3, 2026, to make available its PFIC Annual Statement for fiscal year 2025 (January 1 to December 31, 2025) to Class A ordinary shareholders, enabling optional QEF Elections under IRC Section 1295. The statement discloses minimal ordinary earnings of $0.0006411382 per unit per day, zero net capital gains, and no cash or property distributions. No operational or financial performance metrics or period-over-period changes are reported.
- Β·PFIC tax period: January 1, 2025 to December 31, 2025
- Β·Net Capital Gains: $0
- Β·Distributions: Cash NONE; Fair Market Value of property: NONE
- Β·Date of Incorporation: December 18, 2024
- Β·Principal executive offices: 555 Bryant Street, No. 590, Palo Alto, CA 94301
- Β·Trading on Nasdaq Stock Market LLC
- Β·Emerging growth company: Yes
Get daily alerts with 11 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 6 filings
πΊπΈ More from United States
View all βApril 01, 2026
US Pre-Market SEC Filings Roundup β April 01, 2026
US Pre-Market SEC Filings Roundup
April 01, 2026
Dow Jones 30 Stocks SEC Filings β April 01, 2026
Dow Jones 30 Stocks SEC Filings
April 01, 2026
S&P 500 Consumer Discretionary Sector SEC Filings β April 01, 2026
S&P 500 Consumer Discretionary Sector SEC Filings
April 01, 2026
S&P 500 Healthcare Sector SEC Filings β April 01, 2026
S&P 500 Healthcare Sector SEC Filings